TransMedics Group (NASDAQ:TMDX) Receives Hold Rating from Needham & Company LLC

TransMedics Group (NASDAQ:TMDX)‘s stock had its “hold” rating reaffirmed by equities researchers at Needham & Company LLC in a note issued to investors on Wednesday,Benzinga reports.

Other analysts also recently issued reports about the company. Robert W. Baird decreased their price objective on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. Piper Sandler reduced their price target on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a report on Wednesday, December 11th. Canaccord Genuity Group reiterated a “buy” rating and set a $104.00 price objective on shares of TransMedics Group in a research note on Tuesday, March 11th. Oppenheimer reissued an “outperform” rating and issued a $125.00 price objective on shares of TransMedics Group in a research note on Tuesday, December 3rd. Finally, JPMorgan Chase & Co. restated a “neutral” rating and set a $75.00 target price (down previously from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $122.70.

TransMedics Group Stock Up 0.2 %

Shares of NASDAQ:TMDX opened at $70.44 on Wednesday. The business’s 50 day moving average is $68.88 and its 200 day moving average is $88.90. The stock has a market cap of $2.37 billion, a P/E ratio of 74.94 and a beta of 2.12. TransMedics Group has a 52-week low of $55.00 and a 52-week high of $177.37. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Braidwell LP purchased a new stake in TransMedics Group in the fourth quarter valued at about $57,493,000. Norges Bank acquired a new position in TransMedics Group in the 4th quarter worth approximately $22,861,000. Mackenzie Financial Corp raised its position in TransMedics Group by 73.0% during the 4th quarter. Mackenzie Financial Corp now owns 828,147 shares of the company’s stock worth $51,635,000 after buying an additional 349,403 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in TransMedics Group by 1,565.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 269,825 shares of the company’s stock valued at $16,820,000 after acquiring an additional 253,624 shares during the period. Finally, Emerald Advisers LLC boosted its holdings in shares of TransMedics Group by 146.3% in the 4th quarter. Emerald Advisers LLC now owns 371,711 shares of the company’s stock valued at $23,176,000 after acquiring an additional 220,804 shares during the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.